A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) (CheckMate-1533)

NCT06946797 PHASE2 RECRUITING

The purpose of this study is to evaluate two dosing regimens of subcutaneous Nivolumab in combination with intravenous Ipilimumab and chemotherapy in participants with previously untreated metastatic or recurrent Non-Small Cell Lung Cancer (NSCLC)

Details

Lead sponsor	Bristol-Myers Squibb
Phase	PHASE2
Status	RECRUITING
Enrolment	76
Start date	Fri Sep 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Oct 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Non-Small Cell Lung Cancer

Interventions

• Nivolumab
• Ipilimumab
• Carboplatin
• Paclitaxel
• Pemetrexed
• Cisplatin

Countries

France, Italy, South Africa, Greece, Chile, Poland, Mexico, Romania, United States, Turkey (Türkiye), Brazil